Markus Berger

Hospital de Clínicas de Porto Alegre — Brazil

Biochemistry, Genetics and Molecular Biology · Life Sciences

43h-index5.4kcitations234works2.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Glycosylation and Glycoproteins Research(31), Lung Cancer Treatments and Mutations(19), HER2/EGFR in Cancer Research(17), Monoclonal and Polyclonal Antibodies Research(16), Carbohydrate Chemistry and Synthesis(11)

Publications234 total

Transposable elements hitchhike on Starships across fungal genomes
Nature Communications·2026· 1 citedOpen Access
Table S1 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026Open Access
Figure S4 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026Open Access
Figure S6 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026Open Access
Table S4 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026Open Access
Figure S2 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026Open Access
Data from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026Open Access
Figure S5 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026Open Access
Supplementary Methods 1 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026Open Access
Figure S7 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026Open Access
Table S2 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026Open Access
Table S5 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026Open Access
Figure S3 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026Open Access
Figure S8 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026Open Access
Table S3 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026Open Access
Figure S1 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026Open Access
An insight into the ovary and midgut transcriptome of Dermacentor nitens tick
Ticks and Tick-borne Diseases·2026Open Access
Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
Cancer Discovery·2025· 3 citedOpen Access
Quantum and quantum-inspired computing in civil engineering
Advanced Engineering Informatics·2025· 1 citedOpen Access
Patterns of Failure and Toxicity in Patients with N2 vs. N3 Disease Undergoing Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer
International Journal of Radiation Oncology*Biology*Physics·2025Open Access
page 1 of 12Next →

Frequent Co-authors

Véronique Blanchard(10), Walter O. Beys‐da‐Silva(8), Jorge A. Guimarães(8), Lucélia Santi(7), Thomas M. Stulnig(5), R Tauber(5), Floyd E. Romesberg(4), Marilene Henning Vainstein(4), Stephan Hinderlich(4), Marcus Bauser(4), Matthias Kaup(4), Dominique Petzold(3), André Winkler(3), Constanze Heß(3), Marc Ehlers(3), Jörg Köhl(3), W. Waldhäusl(3), Hartmut Rehwinkel(3), Yiqin Wu(3), Anthony K. Ogawa(3)